Signal Detection and Management in Pharmacovigilance

Identify signals via signal detection and progress through validation, prioritization, assessment, risk classification, and action recommendations. Use ICSRs and data sources with qualitative or quantitative methods, documented within 5–7 days.

Prioritize signals during validation by assessing impact on patients or public health and on the risk-benefit balance, and by evaluating severity, outcome, reversibility, frequency, vulnerable populations, and available alternatives.

Explore the evaluation process in pharmacovigilance, confirming signals through medical assessment, case definitions, and rigorous data review to determine causal links between adverse events and medicines.

Classify pharmacovigilance risks after validation into identified and potential categories based on evidence, guiding prompt action, reporting to competent authorities, and product label updates.

In pharmacovigilance signal management, the safety management team recommends actions based on risk, and the safety physician exchanges information with regulatory authorities and marketing authorisation holders to communicate outcomes.

Review data from internal safety databases, literature, and clinical studies with the safety physician; categorize sentinel or chronology-linked cases and assess signal validity using Vigibase and Eudravigilance disproportionality analyses.

Draft a signal assessment report, the safety evaluation after signal detection, prioritization, validation, and risk classification, and structure it with summary, sources, discussion, and references.